Cencora, Inc. $COR Shares Bought by New York State Common Retirement Fund

New York State Common Retirement Fund lifted its stake in shares of Cencora, Inc. (NYSE:COR) by 20.2% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 139,971 shares of the company’s stock after purchasing an additional 23,477 shares during the period. New York State Common Retirement Fund owned 0.07% of Cencora worth $41,970,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the stock. Harbour Investments Inc. boosted its stake in Cencora by 23.6% during the first quarter. Harbour Investments Inc. now owns 937 shares of the company’s stock worth $261,000 after buying an additional 179 shares during the last quarter. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund purchased a new position in shares of Cencora during the 1st quarter worth $389,000. Liberty Wealth Management LLC acquired a new position in shares of Cencora during the 1st quarter valued at about $4,962,000. Cheviot Value Management LLC acquired a new position in shares of Cencora during the 1st quarter valued at about $522,000. Finally, Scotia Capital Inc. grew its holdings in shares of Cencora by 0.7% in the first quarter. Scotia Capital Inc. now owns 7,841 shares of the company’s stock valued at $2,180,000 after purchasing an additional 55 shares during the period. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Cencora in a research note on Tuesday, November 25th. UBS Group raised their price target on shares of Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a report on Friday, November 7th. JPMorgan Chase & Co. upped their price objective on Cencora from $344.00 to $417.00 and gave the company an “overweight” rating in a report on Tuesday, November 11th. Wells Fargo & Company increased their price objective on Cencora from $354.00 to $405.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 11th. Finally, TD Cowen lifted their target price on Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, November 10th. Nine analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, Cencora has a consensus rating of “Moderate Buy” and a consensus target price of $371.09.

Insider Activity

In related news, Chairman Steven H. Collis sold 31,350 shares of the firm’s stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the completion of the transaction, the chairman directly owned 305,913 shares in the company, valued at $88,671,942.18. This trade represents a 9.30% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Robert P. Mauch sold 5,097 shares of the business’s stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the sale, the chief executive officer owned 37,940 shares in the company, valued at $12,398,792. This trade represents a 11.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 46,640 shares of company stock worth $14,099,338. 10.80% of the stock is owned by corporate insiders.

Cencora Stock Performance

Shares of COR stock opened at $368.93 on Monday. The company has a debt-to-equity ratio of 3.64, a quick ratio of 0.53 and a current ratio of 0.90. The firm has a market cap of $71.53 billion, a P/E ratio of 37.96, a P/E/G ratio of 1.56 and a beta of 0.63. The firm’s 50 day moving average price is $335.71 and its 200-day moving average price is $307.83. Cencora, Inc. has a one year low of $223.92 and a one year high of $377.54.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.79 by $0.05. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The company had revenue of $83.73 billion for the quarter, compared to analyst estimates of $83.36 billion. During the same quarter in the previous year, the company earned $3.34 earnings per share. The firm’s quarterly revenue was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, equities research analysts predict that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 14th will be issued a $0.60 dividend. The ex-dividend date is Friday, November 14th. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. This is a boost from Cencora’s previous quarterly dividend of $0.55. Cencora’s dividend payout ratio (DPR) is presently 30.19%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.